Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Biotechnology

Healthcare
$0.46 -0.01%

-$0.00 today

Market cap
$57.32M
Beta
0.96
P/E (TTM)
-2.5
EPS (TTM)
-$0.52
52W Low $1.00High $3.06

Volume 2.23M

Average 1.99M

MIST Total Debt

Short-term and long-term borrowings combined.

Milestone Pharmaceuticals Inc.NASDAQ: MIST

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt rises 147.1% from a year ago

Total debt stood at $137.33M at the end of Q1 FY2026, up 147.1% from a year earlier and up 135.2% from the prior quarter. Over 3 fiscal years it compounded at +186.2% a year.

Context

  • Total debt amounted to 70.9% of total assets at the end of Q1 FY2026, down 18.9 pp from a year earlier.
  • Total debt increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +147.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$137.33M+135.2% QoQ
Last fiscal yearDec 2025
$58.38M+6.5% YoY
Year agoMar 2025
$55.59M+147.1% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+147.1%——
1 year+6.5%——
3-year CAGR+186.2%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
58.38M USD
Year-over-year change
+6.5%
4-year CAGR
+202.4%

Total Debt vs competitors

How MIST compares with its peers on the latest reported figures

  • Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +147.1% is the 2nd highest of 8, against a peer median of -27.2%.
  • Total debt amounts to 70.9% of total assets for MIST, versus a peer median of 7.6%.
MIST Competitors
Total Debt for MIST and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MISTMilestone Pharmaceuticals Inc.Mar 2026$137.33M USD+147.1%+186.2%70.9%
IPHAInnate Pharma S.A.Dec 2025€22.56M EUR-27.2%-18.9%36.0%
PEPGPepGen Inc.Mar 2026$16.56M USD-9.4%-11.5%10.6%
ELTXElicio Therapeutics, Inc.Mar 2026$14.34M USD+147.6%+24.7%63.2%
RANIRani Therapeutics Holdings, Inc.Mar 2026$3.94M USD-84.6%-47.7%7.6%
MOLNMolecular Partners AGMar 2026CHF 3.33M CHF+55.7%-9.1%3.8%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$1.21M USD-57.8%-59.8%0.8%
CRDFCardiff Oncology, Inc.Mar 2026$646K USD-52.4%-32.6%1.3%
Peer median (excluding MIST) —-27.2%-18.9%7.6%

Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents114.14M7.64M13.76M25.31M73.05M
Short-term Investments056.95M52.24M44.38M32.91M
Net Receivables483K1.21M3.85M2.39M3.51M
Inventory0000648K
Other Current Assets00000
Total Current Assets118.92M71.8M73.03M73.93M111.92M
Property, Plant & Equipment (Net)926K2.68M2.19M1.57M1.64M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets926K2.68M2.19M1.57M1.64M
Total Assets119.85M74.48M75.23M75.5M113.56M
Account Payables4.38M2.26M3.98M1.93M5.65M
Short-term Debt224K495K00647K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities709K808K1.99M(0)5.23M
Total Current Liabilities6.78M6.14M7.23M8.13M13.98M
Long-term Debt0049.77M53.35M57.19M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities000083K
Total Non-current Liabilities474K2M51.23M54.23M57.81M
Total Liabilities7.25M8.14M58.46M62.35M71.79M
Common Stock251.9M273.9M260.5M288.05M352.62M
Retained Earnings(206.32M)(266.34M)(326.03M)(367.55M)(430.6M)
Accumulated OCI51.31M34.35M48.46M53.08M55.65M
Other Stockholders Equity00000
Minority Interest00000
Total Equity112.6M66.35M16.77M13.15M41.77M
Total Debt698K2.49M51.78M54.8M58.38M
Net Debt(113.44M)(5.15M)38.02M29.48M(14.67M)

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Intrinsic Alpha fair value

Locked

Current Price

$0.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.